Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications — a comprehensive review and medicolegal warning for anesthesiologists
Article information
Korean Journal of Anesthesiology 2026;79(4):395-404
DOI: https://doi.org/10.4097/kja.26375
The article by Kwak HJ, et al. entitled, “Blamed but not at fault: anti-obesity medication adverse effects misidentified as perioperative complications — a comprehensive review and medicolegal warning for anesthesiologists” (Korean J Anesthesiol 2026;79(4):395-404) contained several inaccuracies in the literature cited to support specific clinical recommendations, identified during post-publication review. These are corrected below, with the affected page of the original article noted for each item.
1. Page 397–398, “Propofol and benzodiazepines”
Before correction (p. 397–398):
“Obesity substantially alters the pharmacokinetics of highly lipophilic anesthetic agents, including propofol and benzodiazepines, through an increased volume of distribution, altered plasma protein binding, and changes in hepatic blood flow. To avoid prolonged sedation, dosing should be guided by lean body weight for induction and total body weight for the maintenance of infusions. In patients with GLP-1 RAs, delayed gastric emptying may attenuate the oral benzodiazepine absorption rate, and emerging evidence suggests that incretin signaling may modulate hepatic cytochrome P450 3A4 activity. Propofol is a lipid emulsion that provides approximately 1.1 kcal/mL, which should be considered when managing blood glucose in patients receiving concurrent insulin or sulfonylurea therapy, as it may contribute to glycemic variability [22,23].”
The correct information is found below:
“Obesity substantially alters the pharmacokinetics of highly lipophilic anesthetic agents, including propofol and benzodiazepines, through an increased volume of distribution and changes in regional blood flow [22,46]. Propofol dosing should be guided by lean body weight for induction and total body weight for maintenance of infusions [46], whereas benzodiazepine loading doses should be based on actual body weight, with maintenance guided by ideal body weight [22]. Propofol is a lipid emulsion that provides approximately 1.1 kcal/mL [47], an unrecognized caloric load that can contribute to glycemic instability in patients receiving concurrent insulin or sulfonylurea therapy.”
Reference 46 and 47 have been added: [46] Ingrande J, Lemmens HJ. Dose adjustment of anaesthetics in the morbidly obese. Br J Anaesth 2010;105(Suppl 1):i16–i23. doi:10.1093/bja/aeq312. [47] Buckley CT, Dickerson RN. Propofol: a risk factor for caloric overfeeding and inadequate protein delivery. Hosp Pharm 2020;55(3):151–152. doi:10.1177/0018578719888908.
2. Page 399, “Drug-induced acute pancreatitis”
Before correction (p. 399):
“A history of pancreatitis constitutes a relative contraindication to GLP-1 RA therapy and must be elicited during preoperative assessment [31].”
The correct information is found below:
“A history of pancreatitis is not a formal contraindication to GLP-1 RA therapy; product labeling recommends monitoring for pancreatitis symptoms rather than prohibiting use [33], and real-world data suggest the risk is manageable with informed decision-making [31]. A history of pancreatitis should nonetheless be elicited during preoperative assessment to guide postoperative differential diagnosis [31].”
3. Page 400, “Preoperative drug cessation protocols” and Table 4
Before correction (p. 400):
“For tirzepatide (T½ ~5 days), many experts advocate a two-week cessation interval [4,5,37].”
The correct information is found below:
“For tirzepatide (T½ ~5 days), recommendations diverge. Earlier guidance extrapolated the ASA’s 1-week hold interval for weekly GLP-1 RA formulations to tirzepatide [4], whereas the most recent multidisciplinary consensus instead recommends continuing GIP/GLP-1 dual agonists throughout the perioperative period with risk-mitigation strategies (individualized aspiration-risk assessment, gastric ultrasound where available) rather than cessation [37]. A validated, tirzepatide-specific cessation interval has not yet been established.”
Table 4, “Tirzepatide weekly” row — before correction:
Recommended hold: “≥ 1 week (consider ≥ 2 weeks)*”; Guideline source: “Expert consensus [37]”.
The correct information is found below:
Recommended hold: “No validated interval; continue throughout the perioperative period per most recent guidance, or ≥ 1 week if extrapolating the weekly-formulation hold†”; Guideline source: “ASA 2023; Anesthesia 2025 [4,37]”. The full corrected table is reproduced at the end of this corrigendum.
4. Page 401, “Blood glucose monitoring” and Practical perioperative checklist
Before correction (p. 401, body text):
“Intraoperative blood glucose monitoring every 1–2 h is recommended, targeting 6–10 mmol/L (108–180 mg/dL). Continuous glucose monitoring devices should not be used as the sole intraoperative monitoring modality, as they have been shown to be unreliable in the perioperative setting [23].”
The correct information is found below:
“Intraoperative blood glucose monitoring frequency should be individualized: every 30 min–2 h in patients receiving IV insulin infusion, and less frequently otherwise, targeting 7.8–10.0 mmol/L (140–180 mg/dL); targets below 6.1 mmol/L (110 mg/dL) are not recommended [23]. Continuous glucose monitoring devices should not be used as the sole monitoring modality, as their reliability is limited in the hypoglycemic range [23].”
Before correction (Practical perioperative checklist, p. 401):
“Monitor blood glucose every 1–2 h; the target is 6–10 mmol/L [23].”
The correct information is found below:
“Monitor blood glucose per clinical context (every 30 min–2 h if on IV insulin infusion); target 7.8–10.0 mmol/L (140–180 mg/dL) [23].”
5. Page 400–401, “Centrally acting agents” and Table 4 (Phentermine, Bupropion/Naltrexone)
Before correction (p. 400–401):
“Phentermine-containing agents should be discontinued at least 14 days before elective surgery. Similarly, bupropion/naltrexone should be ceased 14 days preoperatively to allow CYP2D6 recovery and reduce the risks of serotonin syndrome, seizures, and opioid antagonism [15,16].”
The correct information is found below:
“Phentermine-containing agents should be discontinued approximately 1 week (7 days) before elective surgery [48]. Bupropion may be continued through the perioperative period per psychiatric-medication consensus guidance [49], with attention to seizure-threshold-lowering interactions [16]; naltrexone (elimination half-life ~4 h; active metabolite 6β-naltrexol ~13 h [50]), however, should be considered for discontinuation when significant postoperative opioid analgesia is anticipated; a standardized preoperative cessation interval based on clinical outcome data has not yet been established.”
References 48, 49, and 50 have been added: [48] Stephens LC, Katz SG. Phentermine and anaesthesia. Anaesth Intensive Care 2005;33(4):525–527. doi:10.1177/0310057X0503300418. [49] Oprea AD, Keshock MC, O’Glasser AY, et al. Preoperative management of medications for psychiatric diseases: Society for Perioperative Assessment and Quality Improvement consensus statement. Mayo Clin Proc 2022;97(2):397–416. doi:10.1016/j.mayocp.2021.11.011. [50] REVIA (naltrexone hydrochloride) tablets, prescribing information. U.S. Food and Drug Administration; 2013.
Table 4 has been revised accordingly; the full corrected table is reproduced below.
The authors would like to apologize for any inconvenience caused.